Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

The First Korean Case of VEXAS Syndrome Caused by a UBA1 Somatic Variant

  • Jihoon G. Yoon (Department of Genomic Medicine, Seoul National University Hospital) ;
  • Seungbok Lee (Department of Genomic Medicine, Seoul National University Hospital) ;
  • Sheehyun Kim (Department of Genomic Medicine, Seoul National University Hospital) ;
  • Man Jin Kim (Department of Genomic Medicine, Seoul National University Hospital) ;
  • Yoon Hwan Chang (Department of Laboratory Medicine, Seoul National University Hospital) ;
  • Jin Kyun Park (Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital) ;
  • Dong-Yeop Shin (Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital) ;
  • Jangsup Moon (Department of Genomic Medicine, Seoul National University Hospital)
  • Received : 2022.06.10
  • Accepted : 2022.09.14
  • Published : 2023.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

Acknowledgement

This research was supported by funds from the Research of Korea Centers for Disease Control and Prevention (2020-ER6904-01) and the Seoul National University Hospital Research Fund (0320210170).

References

  1. Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 2020;383:2628-38. https://doi.org/10.1056/NEJMoa2026834
  2. Arlet JB, Terrier B, Kosmider O. Mutant UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 2021;384:2163. https://doi.org/10.1056/NEJMc2102124
  3. Stubbins RJ, McGinnis E, Johal B, Chen LY, Wilson L, Cardona DO, et al. VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome). Haematologica 2022;107:1011-3. https://doi.org/10.3324/haematol.2021.280238
  4. Georgin-Lavialle S, Terrier B, Guedon AF, Heiblig M, Comont T, Lazaro E, et al. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol 2022;186:564-74. https://doi.org/10.1111/bjd.20805
  5. Stubbins RJ, Cherniawsky H, Chen LYC, Nevill TJ. Innovations in genomics for undiagnosed diseases: vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. CMAJ 2022;194:E524-7. https://doi.org/10.1503/cmaj.211770
  6. Bourbon E, Heiblig M, Gerfaud Valentin M, Barba T, Durel CA, Lega JC, et al. Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood 2021;137:3682-4. https://doi.org/10.1182/blood.2020010177
  7. Kunishita Y, Kirino Y, Tsuchida N, Maeda A, Sato Y, Takase-Minegishi K, et al. Case report: tocilizumab treatment for VEXAS syndrome with relapsing polychondritis: a single-center, 1-year longitudinal observational study in Japan. Front Immunol 2022;13:901063. https://doi.org/10.3389/fimmu.2022.901063
  8. Poulter JA, Collins JC, Cargo C, De Tute RM, Evans P, Ospina Cardona D, et al. Novel somatic mutations in UBA1 as a cause of VEXAS syndrome. Blood 2021;137:3676-81. https://doi.org/10.1182/blood.2020010286
  9. Templé M, Duroyon E, Croizier C, Rossignol J, Huet T, Friedrich C, et al. Atypical splice-site mutations causing VEXAS syndrome. Rheumatology (Oxford) 2021;60:e435-7. https://doi.org/10.1093/rheumatology/keab524
  10. Lötscher F, Seitz L, Simeunovic H, Sarbu AC, Porret NA, Feldmeyer L, et al. Case report: genetic double strike: VEXAS and TET2-positive myelodysplastic syndrome in a patient with long-standing refractory autoinflammatory disease. Front Immunol 2021;12:800149. https://doi.org/10.3389/fimmu.2021.800149